New Enterprise Associates 16, L.P.

Average Profitability
3.67%
Insider Buys Quantity
5
Insider Buys Sum
$78.27M
Insider Sells Quantity
1
Insider Sells Sum
$3,000.48

Insider Activity of New Enterprise Associates 16, L.P.

According to the SEC Form 4 filings, New Enterprise Associates 16, L.P., being in a position of

  1. 10 percent owner at Marker Therapeutics, Inc.,
    оver the last 12 months, has bought 554250 shares for $1.77M, and sold 0 shares,
    over all time since 2021-03-16, has bought 6268535 shares for $11.77M, and sold 0 shares.

The largest purchase of all time was on 2019-05-09 and amounted to 5000000 shares of Trevi Therapeutics, Inc. for $50M.

The largest sale of all time was on 2020-04-03 and amounted to 1128 shares of Trevi Therapeutics, Inc. for $3,000.

Biography of New Enterprise Associates 16, L.P.

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $1,773,6001100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2024-12-23PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
554,250
5.7713%
$3.20$1.77M-45.61%
2021-10-18PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
3.7M
11.1305%
$0.81$3M+63.35%
2021-03-16PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
5.71M
9.5207%
$1.75$10M-4.3%
2020-04-03SaleTrevi Therapeutics, Inc.
TRVI
10 percent owner
1,128
0.0062%
$2.66$3,000+19.07%
2019-07-22PurchaseMirum Pharmaceuticals, Inc.
MIRM
10 percent owner
900,000
5.3814%
$15.00$13.5M+5.09%
2019-05-09PurchaseTrevi Therapeutics, Inc.
TRVI
10 percent owner
5M
34.6117%
$10.00$50M-42.9%
Total: 6
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.